Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.44 |
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650416 | 0.91 | KMT2A (0.44) | LRRK2ROCK2ROCK1BRD4NAMPT | |
| SCHEMBL5652045 | 0.87 | PRMT5 (0.52) | ROCK2ROCK1NAMPT | |
| SCHEMBL5653577 | 0.79 | PRMT5 (0.45) | NAMPT | |
| SCHEMBL5651330 | 0.79 | DRD2 (0.55) | — | |
| SCHEMBL5650810 | 0.77 | KMT2A (0.41) | ROCK2ROCK1 | |
| SCHEMBL5651703 | 0.76 | MEN1 (0.54) | — | |
| SCHEMBL5654821 | 0.76 | CYP2D6 (0.56) | — | |
| SCHEMBL5651513 | 0.75 | DRD2 (0.52) | — | |
| SCHEMBL5652205 | 0.74 | GAA (0.44) | — | |
| SCHEMBL5650784 | 0.73 | GAA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | LRRK2 2726/4885SUV39H2 304/4885ROCK2 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.